Dyskinesia and Parkinson's disease: Research papers
- Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia
The review will consider the biochemical evidence indicating that the serotonergic neurons are involved in the dopaminergic effects of L-DOPA in the brain. The consequences are an ectopic and aberrant release of dopamine that follows the serotonergic innervation of the brain.
01 January 2012
- What Factors Influence Motor Complications in Parkinson Disease?: A 10-Year Prospective Study
By the end of the first decade, most patients exhibited dyskinesias (91%), motor fluctuations (62%), and freezing of gait (68%). An association was found between several patients' characteristics and presence of motor complications by 5 years, though not after 10 years of follow up.
01 December 2011
- Complexity of Motor Response to Different Doses of Duodenal Levodopa Infusion in Parkinson Disease
Conclusions: Motor response from different doses of levodopa/carbidopa intestinal gel is in a broad sense predictable even in dyskinetic patients although major interindividual differences in dose requirement, plasma levels, and motor response are found.
16 November 2011
- Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease
The A-allele of the COMT Val158Met polymorphism was related to an increased risk of developing dyskinesias during follow-up, in a dose-dependent manner (adjusted hazard ratios for the AG and AA genotypes [compared to GG]: 2.09 [95% confidence interval (CI), 1.074.06] and 2.81 [CI, 1.435.54], respectively).
14 November 2011
- Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task
In particular, PD patients with levodopa-induced dyskinesia showed significant overactivity in the supplementary motor area and underactivity in the right inferior prefrontal gyrus during execution of both tasks when compared with PD patients without levodopa-induced dyskinesia.
10 November 2011
- Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias
The study used 11C-CNS 5161 [N-methyl-3(thyomethylphenyl)cyanamide] positron emission tomography, a marker of activated N-methyl-d-aspartate receptor ion channels, to compare in vivo glutamate function in parkinsonian patients with and without levodopa-induced dyskinesias.
02 March 2011
